FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets
Patent has potential for applications beyond diabetes, including other cell and tissue transplantation procedures HOUSTON, Aug. 11, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with...
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


